Clinical Trial Detail

NCT ID NCT02053376
Title A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors University of Pittsburgh
Indications

biliary tract cancer

cholangiocarcinoma

Therapies

Regorafenib

Age Groups: adult

No variant requirements are available.